For research use only. Not for use in humans.

Anrukinzumab (Anti-IL-13)

Synonyms: IMA-638 Cat.No.A2665 Purity:99%

Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD.

Anrukinzumab (Anti-IL-13)

Quality Control

Batch: A266501 Purity: 99% Protein concentration: 7.55mg/ml Endotoxin Level: ＜1EU/mg

99

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD.
References	https://pubmed.ncbi.nlm.nih.gov/25567115/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	910649-32-0
Molecular Weight	150
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.